Drugs & Targets MCW Cancer Center leads change in Medicare policy for older patients with MDS in need of alloHCT May 10, 2024Vol.50 No.19
Drugs & Targets EMA validates application for Opdivo + Yervoy for MSI-H/dMMR mCRC May 10, 2024Vol.50 No.19
Drugs & Targets FDA issues additional draft guidance on eligibility criteria for cancer drug clinical trials May 03, 2024Vol.50 No.18
Drugs & Targets CHMP recommends approval of fruquintinib for previously-treated mCRC May 03, 2024Vol.50 No.18
Drugs & Targets FDA approves Anktiva for non-muscle-invasive bladder cancer April 26, 2024Vol.50 No.17
Drugs & Targets Health Canada approves Keytruda for gastroesophageal cancer April 26, 2024Vol.50 No.17
Drugs & Targets European Commission approves Xtandi for high-risk BCR nmHSPC April 26, 2024Vol.50 No.17
Drugs & Targets CHMP recommends approval of Opdivo combination for urothelial carcinoma April 26, 2024Vol.50 No.17
